Wed. Jul 6th, 2022
T

he NHS is to prescribe a new weight loss jab in order to tackle the obesity crisis in England.

The National Institute of Health and Care Excellence (Nice) is set to approve the new drug, Wegovy, which has been described as a “game-changer” by researchers.

Trials of the drug, created by Novo Nordisk, found those put on the treatment lost an average of 2.5 stone in comparison with those on the placebo. One in three lost an average of a fifth of their total body weight.

According to The Telegraph, the drug is to be taken once a week and will be recommended for those with a body mass index of 30 or over if they have been referred for specialist help, and to anyone with a BMI of 35 or more with a weight-related health problem.

Rachel Batterham, lead researcher for the project and professor of obesity, diabetes and endocrinology at University College London said: “No other drug has come close to producing this level of weight loss – this really is a gamechanger.

“For the first time, people can achieve through drugs what was only possible through weight-loss surgery.”

The drug works by hijacking the body’s appetite regulating system in the brain, leading to reduced hunger and calorie intake.

Pinder Sahota, the general manager of Novo Nordisk UK, previously said: “We’re hopeful that Wegovy being made available on the NHS in England will help thousands of people living with obesity.”

According to The Health Survey for England, 68 per cent of men between 16-75 were overwieght or obese.

For women, 60 per cent were classified as obese or overwieght in 2019.

Among children, 18 per cent of boys and 13 per cent of girls were obese.

The Department for Health and Social Care introduced calorie labelling on menus in cafes and takeaways which will come into force from April 2022.

By

Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Wizadclick | WAC MAG 2022